Discover Ono Pharmaceutical's groundbreaking patent for autophagy-inhibiting compounds, targeting various cancers with innovative MEK inhibitors like selumetinib.

近年来随着治疗靶点的发现和新型靶向药物的不断研发，肿瘤治疗已步入精准治疗新时代。近日，2024 年世界肺癌大会（WCLC）和欧洲肿瘤内科学会（ESMO）年会陆续召开，带来肿瘤领域最新前沿进展。会议中，针对 BRAF、MET 14 ...

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Researchers at the University of Massachusetts Amherst and UMass Chan Medical School have demonstrated in mice a new method ...

根据在FGFR2 融合+ ICC 细胞中抑制 FGFR后观察到的代谢可塑性，我们接下来探索了针对新出现的代谢弱点提高疗效的可能性。为此，我们测试了联合抑制FGFR和线粒体氧化代谢的效果。ONC212是一种对线粒体蛋白质量控制至关重要的ClpP蛋白酶激动剂，ONC212增强了FGFRi 在ICC13-7 和ICC21 细胞中的疗效，还研究了降低葡萄糖条件对这些反应的影响发，现，ONC212与 ...

Innovative use of lipid nanoparticles to deliver immune agonists shows promise in activating anti-tumor immunity in ...

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

While neoadjuvant therapy in stage III or great melanoma is already the standard of care, new research presented at ESMO ...

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.